IL-4/10 prevents stress vulnerability following imipramine discontinuation

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Han, Arum ^a   Yeo, Hyelim ^a,b   Park, Min Jung ^a   Kim, Seung Hyun ^b   Choi, Hyun Jin ^a   Hong, Chang Won ^c   Kwon, Min Soo ^a  

^a CHA University   (South Korea)

^b Hanyang University   (South Korea)

^c Hallym University   (South Korea)

Author keywords

Depression; IL 10; IL 4; Microglia; Stress vulnerability

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; IMIPRAMINE; INTERLEUKIN 10; INTERLEUKIN 4; KYNURENINE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 4; SEROTONIN RECEPTOR; RECOMBINANT PROTEIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG TARGETING; FOOTSHOCK; HIPPOCAMPUS; IMMOBILIZATION STRESS; LYMPH NODE; MALE; MICROGLIA; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; RELAPSE; STRESS; STRESS VULNERABILITY; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; C57BL MOUSE; DRUG EFFECTS; ELECTRIC SHOCK; EXERCISE; EXPLORATORY BEHAVIOR; FOOD PREFERENCE; MENTAL STRESS; PATHOLOGY; PSYCHOLOGY; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; ELECTROSHOCK; EXPLORATORY BEHAVIOR; FOOD PREFERENCES; HIPPOCAMPUS; IMIPRAMINE; INTERLEUKIN-10; INTERLEUKIN-4; LYMPH NODES; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; RECOMBINANT PROTEINS; RESTRAINT, PHYSICAL; STRESS, PSYCHOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84946490672     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0416-3     Document Type: Article

References (68)

1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358:55-68.
2. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55:1128-32.
3. Teasdale JD, Segal ZV, Williams JMG, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol. 2000;68:615-23.
4. Blume J, Douglas SD, Evans DL. Immune suppression and immune activation in depression. Brain Behav Immun. 2011;25:221-9.
5. Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: From serotonin to kynurenine. Psychoneuroendocrinology. 2011;36:426-36.
6. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-41.
7. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12:988-1000.
8. Myint AM, Kim YK. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses. 2003;61:519-25.
9. Kubera M, Basta-Kaim A, Papp M. The effect of chronic treatment with imipramine on the immunoreactivity of animals subjected to a chronic mild stress model of depression. Immunopharmacology. 1995;30:225-30.
10. Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, Baratta MV, et al. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry. 2013;19:699-709.
11. Irwin MR, Miller AH. Depressive disorders and immunity: 20years of progress and discovery. Brain Behav Immun. 2007;21:374-83.
12. Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res. 2002;53:873-6.
13. Roque S, Correia-Neves M, Mesquita AR, Palha JA, Sousa N. Interleukin-10: a key cytokine in depression? Cardiovascular Psychiatry Neurology. 2009;2009:1-5.
14. Kubera M, Lin A-H, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-[gamma]/interleukin-10 production ratio. J Clin Psychopharmacol. 2001;21:199-206.
15. Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology. 1999;20:370-9.
16. Miller AH. Depression and immunity: a role for T cells? Brain Behav Immun. 2010;24:1-8.
17. Walker FR, Nilsson M, Jones K. Acute and chronic stress-induced disturbances of microglial plasticity, phenotype and function. Curr Drug Targets. 2013;14:1262-76.
18. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6:219-33.
19. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol. 2011;11:775-87.
20. Olah M, Biber K, Vinet J, Boddeke HW. Microglia phenotype diversity. CNS Neurol Disord Drug Targets. 2011;10:108-18.
21. Nair A, Bonneau RH. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroendocrinol. 2006;171:72-85.
22. Tynan RJ, Naicker S, Hinwood M, Nalivaiko E, Buller KM, Pow DV, et al. Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain Behav Immun. 2010;24:1058-68.
23. Sugama S, Fujita M, Hashimoto M, Conti B. Stress induced morphological microglial activation in the rodent brain: involvement of interleukin-18. Neuroscience. 2007;146:1388-99.
24. Dingell JV, Sulser F, Gillette JR. Species differences in the metabolism of imipramine and desmethylimipramine (DMI). J Pharmacol Exp Ther. 1964;143:14-22.
25. Kwon MS, Seo YJ, Shim EJ, Lee JK, Jang JE, Park SH, et al. The differential effects of emotional or physical stress on pain behaviors or on c-Fos immunoreactivity in paraventricular nucleus or arcuate nucleus. Brain Res. 2008;1190:122-31.
26. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl). 1987;93:358-64.
27. Crawley J, Goodwin FK. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav. 1980;13:167-70.
28. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav. 1986;24:525-9.
29. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985;85:367-70.
30. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977;266:730-2.
31. Kim K-S, Han P-L. Optimization of chronic stress paradigms using anxiety- and depression-like behavioral parameters. J Neurosci Res. 2006;83:497-507.
32. Han A, Sung YB, Chung SY, Kwon MS. Possible additional antidepressant-like mechanism of sodium butyrate: targeting the hippocampus. Neuropharmacology. 2014;81:292-302.
33. Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun. 2014;42:50-9. doi: 10.1016/j.bbi.2014.05.007.
34. Clark SM, Sand J, Francis TC, Nagaraju A, Michael KC, Keegan AD, et al. Immune status influences fear and anxiety responses in mice after acute stress exposure. Brain Behav Immun. 2014;38:192-201. doi: 10.1016/j.bbi.2014.02.001.
35. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516-8.
36. Duman RS. Depression: a case of neuronal life and death? Biol Psychiatry. 2004;56:140-5.
37. Luo XG, Chen SD. The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener. 2012;1:9.
38. Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry. 2000;48:732-9.
39. Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol Clin Exp. 2001;16:95-103.
40. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5:401-12.
41. Sallusto F, Impellizzieri D, Basso C, Laroni A, Uccelli A, Lanzavecchia A, et al. T-cell trafficking in the central nervous system. Immunol Rev. 2012;248:216-27.
42. Frick LR, Barreiro Arcos ML, Rapanelli M, Zappia MP, Brocco M, Mongini C, et al. Chronic restraint stress impairs T-cell immunity and promotes tumor progression in mice. Stress: Intl J Biology Stress. 2009;12:134-43.
43. Cao G, Yang Q, Zhang S, Xu C, Roberts AI, Wang Y, et al. Mesenchymal stem cells prevent restraint stress-induced lymphocyte depletion via interleukin-4. Brain Behav Immun. 2014;38:125-32.
44. Cohen H, Ziv Y, Cardon M, Kaplan Z, Matar MA, Gidron Y, et al. Maladaptation to mental stress mitigated by the adaptive immune system via depletion of naturally occurring regulatory CD4 + CD25+ cells. J Neurobiol. 2006;66:552-63.
45. Voorhees JL, Tarr AJ, Wohleb ES, Godbout JP, Mo X, Sheridan JF, et al. Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. PLoS ONE. 2013;8, e58488.
46. Mesquita AR, Correia-Neves M, Roque S, Castro AG, Vieira P, Pedrosa J, et al. IL-10 modulates depressive-like behavior. J Psychiatr Res. 2008;43:89-97.
47. Quan N, Herkenham M. Connecting cytokines and brain: a review of current issues. Histol Histopathol. 2002;17:273-88.
48. Yarlagadda A, Alfson E, Clayton AH. The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry (Edgmont). 2009;6:18-22.
49. Banks WA. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des. 2005;11:973-84.
50. Ataka K, Asakawa A, Nagaishi K, Kaimoto K, Sawada A, Hayakawa Y, et al. Bone marrow-derived microglia infiltrate into the paraventricular nucleus of chronic psychological stress-loaded mice. PLoS One. 2013;8, e81744.
51. Reader BF, Jarrett BL, McKim DB, Wohleb ES, Godbout JP, Sheridan JF. Peripheral and central effects of repeated social defeat stress: monocyte trafficking, microglial activation, and anxiety. NSC. 2015;289:429-42.
52. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157:683-94.
53. Ponomarev ED, Maresz K, Tan Y, Dittel BN. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci. 2007;27:10714-21.
54. Melief J, Koning N, Schuurman KG, Van De Garde MD, Smolders J, Hoek RM, et al. Phenotyping primary human microglia: tight regulation of LPS responsiveness. Glia. 2012;60:1506-17.
55. Butovsky O, Bukshpan S, Kunis G, Jung S, Schwartz M. Microglia can be induced by IFN-α or IL-4 to express neural or dendritic-like markers. Mol Cell Neurosci. 2007;35:490-500.
56. Shechter R, London A, Schwartz M. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat Rev Immunol. 2013;13:206-18.
57. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005;26:485-95.
58. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. 2003;3:569-81.
59. Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98.
60. Ramirez K, Shea DT, McKim DB, Reader BF, Sheridan JF. Imipramine attenuates neuroinflammatory signaling and reverses stress-induced social avoidance. Brain Behav Immun. 2015;46:212-20.
61. Schwartz M, Butovsky O, Bruck W, Hanisch UK. Microglial phenotype: is the commitment reversible? Trends Neurosci. 2006;29:68-74.
62. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917-24.
63. Corona AW, Huang Y, O'Connor JC, Dantzer R, Kelley KW, Popovich PG, et al. Fractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharide. J Neuroinflammation. 2010;7:93.
64. Wynne AM, Henry CJ, Huang Y, Cleland A, Godbout JP. Protracted downregulation of CX3CR1 on microglia of aged mice after lipopolysaccharide challenge. Brain Behav Immun. 2010;24:1190-201.
65. Anisman H, Merali Z. Cytokines, stress, and depressive illness. Brain Behav Immun. 2002;16:513-24.
66. Steptoe A, Kunz-Ebrecht SR, Owen N. Lack of association between depressive symptoms and markers of immune and vascular inflammation in middle-aged men and women. Psychol Med. 2003;33:667-74.
67. de Beaurepaire R. Questions raised by the cytokine hypothesis of depression. Brain Behav Immun. 2002;16:610-7.
68. Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci. 2012;109:5995-9.